Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open Label, Dose-Escalation and Expansion Study to Evaluate Safety, Pharmacokinetics and Initial Therapeutic Activity of AVA6103, a Novel FAP-activated Exatecan Administered Intravenously in Subjects With Locally Advanced or Metastatic Selected Solid Tumors

NCT07454642 is registered in ClinicalTrials.gov with Avacta Life Sciences Ltd as lead sponsor.

NCT NCT07454642
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07454642 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open Label, Dose-Escalation and Expansion Study to Evaluate Safety, Pharmacokinetics and Initial Therapeutic Activity of AVA6103, a Novel FAP-activated Exatecan Administered Intravenously in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
Lead sponsor
Avacta Life Sciences Ltd
Phase
Phase 1
Overall status
Recruiting
Start date
March 31, 2026
Completion date
June 30, 2030
Enrollment
174 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

cervical adenocarcinoma, cervical adenosquamous carcinoma, colorectal cancer, gastric adenocarcinoma, gej adenocarcinoma, hormone receptor positive breast carcinoma, pdac - pancreatic ductal adenocarcinoma, small cell carcinoma of lung, vulvar adenocarcinoma